Patent Number: 6,255,112

Title: Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells

Abstract: The invention relates to the induction of hematopoietic stem cells to differentiate into osteoclasts by culturing hematopoietic stem cells with human mesenchymal stem cells, and, in a preferred embodiment, using no exogenous cytokines. Differentiation of the mesenchymal stem cells into osteoblasts inhibited the differentiation of hematopoietic stem cells into osteoclasts. In addition, hematopoietic stem cells can be genetically engineered to carry genes of interest particularly for the expression of physiologically active proteins. In the presence of mesenchymal stem cells, the transduced cells carry the new genetic material and express gene products that can be used to modulate bone resorption.

Inventors: Thiede; Mark A. (Forest Hill, MD), Mbalaviele; Gabriel (Columbia, MD)

Assignee: Osiris Therapeutics, Inc.

International Classification: C12N 5/06 (20060101); C12N 005/06 (); C12N 005/16 ()

Expiration Date: 07/03/2018